349 related articles for article (PubMed ID: 19900407)
21. Induction of C/EBP beta and GADD153 expression by dopamine in human neuroblastoma cells. Relationship with alpha-synuclein increase and cell damage.
Gómez-Santos C; Barrachina M; Giménez-Xavier P; Dalfó E; Ferrer I; Ambrosio S
Brain Res Bull; 2005 Feb; 65(1):87-95. PubMed ID: 15680548
[TBL] [Abstract][Full Text] [Related]
22. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
23. Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70.
Yu F; Xu H; Zhuo M; Sun L; Dong A; Liu X
Biochem Biophys Res Commun; 2005 May; 331(1):278-84. PubMed ID: 15845390
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
25. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
26. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
27. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
28. Extracellular neurosin degrades α-synuclein in cultured cells.
Tatebe H; Watanabe Y; Kasai T; Mizuno T; Nakagawa M; Tanaka M; Tokuda T
Neurosci Res; 2010 Aug; 67(4):341-6. PubMed ID: 20403393
[TBL] [Abstract][Full Text] [Related]
29. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
30. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
[TBL] [Abstract][Full Text] [Related]
32. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
[TBL] [Abstract][Full Text] [Related]
33. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Conway KA; Rochet JC; Bieganski RM; Lansbury PT
Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
[TBL] [Abstract][Full Text] [Related]
34. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
35. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
37. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
38. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
39. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
40. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]